<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Callisto Pharmaceuticals Inc. | Company News & Executive Profiles - KAL | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Callisto Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="10" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Callisto Pharmaceuticals Announces Presentation on SP-304 at the 3rd International Congress on Natural Peptides to Drugs]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_15/ai_n25153740]]></link>
		<description><![CDATA[NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that Dr. Kunwar Shailubhai, Sr. VP Discovery Research, will give a plenary talk covering therapeutic applications of guanylate cyclase C agonist peptides at the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 15 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/dr..html"><![CDATA[Dr.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/u.s.+congress.html"><![CDATA[U.S. Congress]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="tickers">KAL</category>
	</item>
	<item>
		<title><![CDATA[Callisto Pharmaceuticals' Interim Phase II Data of Atiprimod in Advanced Carcinoid Cancer to be presented at ASCO Conference]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_14/ai_n25150813]]></link>
		<description><![CDATA[NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders, announced today that interim data from the company's ongoing open-label Phase II clinical trial of Atiprimod in advanced carcinoid cancer, will be presented at the 44th...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 14 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/asco+plc..html"><![CDATA[Asco Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="tickers">KAL</category>
	</item>
	<item>
		<title><![CDATA[Publication of Early Research on Callisto Pharmaceutical's Degrasyn Drug Class Suggests Potential to Treat Brain Tumors.(Drug overview)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200701/ai_n23592677]]></link>
		<description><![CDATA[NEW YORK, January 23 /PRNewswire/ --    - Paper Published in Oncogene Highlights Animal Model Data on  Degrasyn Drug Candidate WP1066    Callisto Pharmaceuticals, Inc. (Amex: KAL - News; FWB: CA4), a  developer of new drug treatments in the fight against cancer and other...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 23 Jan 2007 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/agent.html"><![CDATA[agent]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/university+of+texas.html"><![CDATA[University of Texas]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="tickers">KAL</category>
	</item>
	<item>
		<title><![CDATA[Callisto Pharmaceuticals' Clinical Study of Atiprimod in Multiple Myeloma Patients Expanded to Additional Clinical Site.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200607/ai_n23550947]]></link>
		<description><![CDATA[NEW YORK, July 27 /PRNewswire/ --    - University of Michigan Comprehensive Cancer Center Commences  Enrollment of Multiple Myeloma Patient in Phase I/IIa Clinical Trial    Callisto Pharmaceuticals, Inc. (Amex: KAL)(FWB:CA4), a developer of  new drug treatments in the fight against cancer and other...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 27 Jul 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/university+of+michigan.html"><![CDATA[University of Michigan]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="tickers">KAL</category>
	</item>
	<item>
		<title><![CDATA[Callisto Announces Sponsored Laboratory Study Agreement With M. D. Anderson Cancer Center on Degrasyn Anticancer Agents.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200606/ai_n23546298]]></link>
		<description><![CDATA[NEW YORK, June 15 /PRNewswire/ --    - Research Agreement to Support Biological Studies on New  Tumor-Fighting Class of Drugs    Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer  of new drug treatments in the fight against cancer and other major  health...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 15 Jun 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agreement.html"><![CDATA[agreement]]></category>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/compound.html"><![CDATA[compound]]></category>
		<category domain="http://resources.bnet.com/topic/dr..html"><![CDATA[Dr.]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/university+of+texas.html"><![CDATA[University of Texas]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="tickers">KAL</category>
	</item>
	<item>
		<title><![CDATA[Callisto Pharmaceuticals Clinical Study of Anti-Leukemia Drug L-Annamycin Expanded to Third Clinical Site; Roswell Park Cancer Institute Commences Enrollment of Adult Leukemia Patients in Phase I/IIa Clinical Trial]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_March_21/ai_n26800339]]></link>
		<description><![CDATA[NEW YORK -- Callisto Pharmaceuticals, Inc. (AMEX:KAL) (FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today announced the expansion of its ongoing research trial of L-Annamycin, the Company's drug candidate to treat adult patients with relapsed or refractory acute lymphocytic leukemia...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 21 Mar 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/roswell+park+cancer+institute.html"><![CDATA[Roswell Park Cancer Institute]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="tickers">KAL</category>
	</item>
	<item>
		<title><![CDATA[HNP, KAL, NETC Have Been On BUYINS.NET Naked Short List For 13 Consecutive Trading Days.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200508/ai_n19864731]]></link>
		<description><![CDATA[M2 PRESSWIRE-19 August 2005-BUYINS.NET: HNP, KAL, NETC Have Been On  BUYINS.NET Naked Short List For 13 Consecutive Trading DaysC1994-2005  M2 COMMUNICATIONS LTD    RDATE:19082005    www.buyins.net, announced today that these select companies have  been on the NASDAQ, AMEX and NYSE naked short threshold...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 19 Aug 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amex.html"><![CDATA[AMEX]]></category>
		<category domain="http://resources.bnet.com/topic/cable.html"><![CDATA[Cable]]></category>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nyse+euronext.html"><![CDATA[NYSE Euronext]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/telecommunications.html"><![CDATA[TELECOMMUNICATIONS]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">KAL,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[GIGA, HNP, KAL, NETC, STLW, VSL have been added to naked short lists today.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200508/ai_n20012299]]></link>
		<description><![CDATA[M2 PRESSWIRE-3 August 2005-BUYINS.NET: GIGA, HNP, KAL, NETC, STLW,  VSL have been added to naked short lists todayC1994-2005 M2  COMMUNICATIONS LTD    RDATE:03082005    BUYINS.NET, www.buyins.net, announced today that these select  companies have been added to the NASDAQ, AMEX and NYSE naked short...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 03 Aug 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amex.html"><![CDATA[Amex]]></category>
		<category domain="http://resources.bnet.com/topic/cable.html"><![CDATA[cable]]></category>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fiber-optics.html"><![CDATA[fiber-optics]]></category>
		<category domain="http://resources.bnet.com/topic/microwave.html"><![CDATA[microwave]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/networking.html"><![CDATA[NETWORKING]]></category>
		<category domain="http://resources.bnet.com/topic/nyse+euronext.html"><![CDATA[NYSE Euronext]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">KAL,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Naked Short Web Site Announces COE, CPN, HNP, KAL, OMNI, PDA Have Been Removed From Threshold Lists Today.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200507/ai_n20006300]]></link>
		<description><![CDATA[M2 PRESSWIRE-27 July 2005-BUYINS.NET: Naked Short Web Site  Announces COE, CPN, HNP, KAL, OMNI, PDA Have Been Removed From Threshold  Lists TodayC1994-2005 M2 COMMUNICATIONS LTD    RDATE:27072005    www.buyins.net, announced today that these select companies have  been removed from the NASDAQ, AMEX and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 27 Jul 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/amex.html"><![CDATA[AMEX]]></category>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/calpine+corp..html"><![CDATA[Calpine Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/coe.html"><![CDATA[COE]]></category>
		<category domain="http://resources.bnet.com/topic/handhelds.html"><![CDATA[Handhelds]]></category>
		<category domain="http://resources.bnet.com/topic/hardware.html"><![CDATA[HARDWARE]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nyse+euronext.html"><![CDATA[NYSE Euronext]]></category>
		<category domain="http://resources.bnet.com/topic/pdas.html"><![CDATA[PDAs]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CPNL Q</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">KAL,CPNL Q,NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Callisto Pharmaceuticals Appoints Dr. Randall K. Johnson to Board of Directors]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_pwwi/is_200502/ai_n9573538]]></link>
		<description><![CDATA[Callisto Pharmaceuticals, Inc. (AMEX: KAL), a biopharmaceutical company primarily focused on the development of drugs to treat cancer and osteolytic bone disease, today announced the appointment of Dr. Randall K. Johnson to its board of directors.  "A seasoned board of directors with first-hand experience in rapidly bringing drug candidates...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 14 Feb 2005 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/callisto+pharmaceuticals+inc..html"><![CDATA[Callisto Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/randall.html"><![CDATA[Randall]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KAL</category>
		<category domain="tickers">KAL</category>
	</item>
</channel>
</rss>
